Mesoblast (NASDAQ:MESO) Upgraded to Hold at StockNews.com

StockNews.com upgraded shares of Mesoblast (NASDAQ:MESO) from a sell rating to a hold rating in a report released on Tuesday morning.

Separately, Cantor Fitzgerald reissued an overweight rating on shares of Mesoblast in a report on Friday, January 12th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of Hold and an average price target of $13.67.

Mesoblast Trading Down 7.0 %

NASDAQ MESO opened at $6.60 on Tuesday. The firm has a market cap of $753.59 million, a price-to-earnings ratio of -5.89 and a beta of 3.59. The company has a 50 day moving average of $3.99 and a 200-day moving average of $2.81. Mesoblast has a 1-year low of $1.61 and a 1-year high of $10.24.

Institutional Trading of Mesoblast

An institutional investor recently raised its position in Mesoblast stock. Lazari Capital Management Inc. lifted its stake in Mesoblast Limited (NASDAQ:MESO) by 9.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 94,034 shares of the company’s stock after purchasing an additional 8,000 shares during the period. Lazari Capital Management Inc. owned 0.06% of Mesoblast worth $116,000 at the end of the most recent quarter. 1.43% of the stock is currently owned by institutional investors and hedge funds.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.